OPRM1 and respiratory depression: Extending this, buprenorphine, a MOR partial agonist with antagonism at KOR/DOR and weak agonism at NOP shows a ceiling effect in respiratory depression assays (Grinnell et al., 2016; Dahan et al., 2005) supporting the premise that favorable multifunctional pharmacology and MOR partial agonism may reduce undesired liabilities while synergistically optimizing analgesia.